Free Trial

Novo Holdings A S Buys 422,860 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP)

ArriVent BioPharma logo with Medical background

Novo Holdings A S increased its stake in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 39.3% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,500,000 shares of the company's stock after acquiring an additional 422,860 shares during the period. ArriVent BioPharma comprises approximately 1.4% of Novo Holdings A S's investment portfolio, making the stock its 24th largest holding. Novo Holdings A S owned 4.48% of ArriVent BioPharma worth $27,825,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. BNP Paribas Financial Markets bought a new stake in ArriVent BioPharma during the first quarter worth about $83,000. American International Group Inc. acquired a new position in ArriVent BioPharma during the first quarter worth approximately $87,000. Rhumbline Advisers increased its position in ArriVent BioPharma by 30.1% during the second quarter. Rhumbline Advisers now owns 12,707 shares of the company's stock worth $236,000 after buying an additional 2,942 shares during the last quarter. Blackstone Inc. acquired a new position in ArriVent BioPharma during the first quarter worth approximately $446,000. Finally, Bank of New York Mellon Corp increased its position in ArriVent BioPharma by 31.4% during the second quarter. Bank of New York Mellon Corp now owns 29,847 shares of the company's stock worth $554,000 after buying an additional 7,140 shares during the last quarter. Institutional investors own 9.48% of the company's stock.

ArriVent BioPharma Price Performance

Shares of ArriVent BioPharma stock traded up $0.24 on Monday, hitting $23.24. The stock had a trading volume of 33,516 shares, compared to its average volume of 177,223. ArriVent BioPharma, Inc. has a twelve month low of $14.35 and a twelve month high of $30.99. The business's 50 day moving average is $23.87 and its two-hundred day moving average is $20.09.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.65) EPS for the quarter, meeting the consensus estimate of ($0.65). Equities research analysts expect that ArriVent BioPharma, Inc. will post -3.03 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on AVBP. HC Wainwright boosted their price target on ArriVent BioPharma from $30.00 to $36.00 and gave the stock a "buy" rating in a research report on Tuesday, September 10th. Oppenheimer reissued an "outperform" rating and set a $39.00 price target (up previously from $35.00) on shares of ArriVent BioPharma in a research report on Tuesday, September 10th. The Goldman Sachs Group boosted their price target on ArriVent BioPharma from $28.00 to $38.00 and gave the stock a "buy" rating in a research report on Tuesday, September 10th. Finally, Citigroup boosted their price target on ArriVent BioPharma from $30.00 to $36.00 and gave the stock a "buy" rating in a research report on Wednesday, September 11th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, ArriVent BioPharma currently has a consensus rating of "Buy" and an average target price of $36.80.

Check Out Our Latest Report on AVBP

ArriVent BioPharma Company Profile

(Free Report)

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.

Read More

Institutional Ownership by Quarter for ArriVent BioPharma (NASDAQ:AVBP)

Should you invest $1,000 in ArriVent BioPharma right now?

Before you consider ArriVent BioPharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ArriVent BioPharma wasn't on the list.

While ArriVent BioPharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Post-Election Chaos or Opportunity? Prepare Your Investments
Strong Markets Meet Rising Volatility—Are Your Investments Safe?
Analysts Bullish on AI-Powered Healthcare: Intuitive Surgical’s 30% Upside

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines